Anagrelide hydrochloride

Pricing Availability Delivery Time Qty
Cat.No. 2432 - Anagrelide hydrochloride | C10H7Cl2N3O.HCl | CAS No. 58579-51-4
Description: Potent PDE3 inhibitor
Alternative Names: BL 4162A
Chemical Name: 6,7-Dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one hydrochloride
Purity: ≥99% (HPLC)

Biological Activity

Potent type III phosphodiesterase (PDE3) inhibitor (IC50 = 36 nM). Inhibits platelet aggregation and produces potent thrombocytopenic effects via inhibition of megakaryocyte maturation.

Technical Data

M. Wt 292.55
Formula C10H7Cl2N3O.HCl
Storage Desiccate at +4°C
Purity ≥99% (HPLC)
CAS Number 58579-51-4
PubChem ID 42786
Smiles ClC1=C(CN(C3)C(N2)=NC3=O)C2=CC=C1Cl.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 2.93 10

Preparing Stock Solutions

The following data is based on the product molecular weight 292.55. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.42 mL 17.09 mL 34.18 mL
5 mM 0.68 mL 3.42 mL 6.84 mL
10 mM 0.34 mL 1.71 mL 3.42 mL
50 mM 0.07 mL 0.34 mL 0.68 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:
Safety Datasheet


References are publications that support the products' biological activity.

Gillespie (1988) Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochem.Pharmacol. 37 2866 PMID: 2456068

Mazur et al (1992) Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 79 1931 PMID: 1562721

Wang et al (2005) Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br.J.Pharmacol. 146 324 PMID: 16041400

If you know of a relevant reference for Anagrelide hydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Phosphodiesterase Inhibitors

Keywords: Anagrelide hydrochloride, supplier, Potent, PDE3, inhibitors, inhibits, Phosphodiesterases, BL4162A, BL, 4162A, Phosphodiesterases, Phosphodiesterases, Tocris Bioscience

Citations for Anagrelide hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for Anagrelide hydrochloride. Do you know of a great paper that uses Anagrelide hydrochloride from Tocris? If so please let us know.

Reviews for Anagrelide hydrochloride

There are currently no reviews for this product. Be the first to review Anagrelide hydrochloride and earn rewards!

Have you used Anagrelide hydrochloride?

Submit a review and receive an Amazon gift card.

$10US/$10CAN/€7/£6 gift card for a review without an image

$25US/$25CAN/€18/£15 gift card for a review with an image

*Offer only valid in the USA / Canada, UK and Europe

Submit a Review

Literature in this Area


Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure

Asthma Poster

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.